Guide

Stemson Therapeutics & Hair Follicle Cloning Timeline to 2030

Hair follicle cloning — engineered de novo hair follicles derived from patient stem cells — represents the ultimate curative threshold for baldness. Stemson Therapeutics leads this biomanufacturing race.

How Stemson Clones Follicles

Stemson uses patient-derived induced pluripotent stem cells (iPSCs) combined with micro-engineered bio-scaffolds to regenerate functional epithelial and dermal papilla cell pairs.

Clinical Trial Progress & 2030 Availability

Following successful human tissue transplantation in rodent models, human Phase 1 safety trials evaluate follicle orientation, hair shaft growth, and immune tolerance.

Frequently asked questions

Is hair cloning available in 2026?

No, hair cloning is currently in clinical trial testing. Commercial availability is targeted for the late 2020s (around 2028-2030).

Related reading: full research article →

More guides

Informational only, not medical advice. Always consult a qualified clinician before starting or changing treatment.